ARTEBRIO-60
Artesunate 60mg Injection
WHO-recommended first-line treatment for severe Plasmodium falciparum malaria including cerebral malaria.
Product Specifications
| Brand Name | ARTEBRIO-60 |
|---|---|
| Generic / Composition | Artesunate IP 60mg + Sodium Bicarbonate solvent + Saline diluent |
| Therapeutic Category | Antimalarial |
| Dosage Form | Lyophilized powder for injection |
| Strength | 60mg |
| Route of Administration | Intravenous / Intramuscular |
| Pack Size | 1 Vial with 1ml sodium bicarbonate + 5ml saline |
| Storage | Store below 25°C. Protect from light. Reconstitute immediately before use. |
| Manufacturer | Biofril Healthcare Pvt. Ltd. · WHO-GMP Plant, Nalagarh HP |
| Prescription Status | Rx — To be sold by retail on the prescription of a Registered Medical Practitioner |
Indications & Clinical Applications
ARTEBRIO-60 is indicated for severe complicated malaria caused by P. falciparum in adults and children, including pregnant women in the 2nd and 3rd trimester.
- Severe Plasmodium falciparum malaria
- Cerebral malaria
- Severe complicated malaria in pregnancy (2nd-3rd trimester)
- Initial parenteral treatment before transitioning to oral ACT
Product Features
- WHO first-line for severe malaria
- Faster parasite clearance than quinine
- Rapid action — improves survival
- WHO-GMP manufactured
- Required reconstitution sequence on insert
Warnings & Precautions
Use full WHO dosing schedule (0, 12, 24 hours then daily). Always follow with full course of oral artemisinin combination therapy after parenteral treatment. Post-treatment delayed haemolysis can occur — monitor haemoglobin 1-3 weeks post-therapy. Pregnancy 1st trimester: only if benefit outweighs risk.
This information is intended for healthcare professionals. Always consult complete product insert and a registered medical practitioner. Report adverse events to biofrilhealthcare@gmail.com.
Enquire About ARTEBRIO-60
PCD franchise · Hospital tenders · Bulk supply